FDA approves supplement for NUVATION's Ibtrozi (NDA219713)Sep 16Regulatory decisionNuvation Bio Inc.taletrectinib
Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake dataAug 6Quarterly updateNuvation Bio Inc.safusidenib
Nuvation Bio registers Phase 1 famotidine interaction study for taletrectinibAug 3Trial updatefamotidineNuvation Bio Inc.
Nuvation Bio's underwriters fully exercise greenshoe on convertible notes offeringJul 6FinancingNuvation Bio Inc.
Sign inSign in